Related Experiment Video

Updated: Mar 7, 2026

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy
11:51

Construction of Defined Human Engineered Cardiac Tissues to Study Mechanisms of Cardiac Cell Therapy

Published on: March 1, 2016

11.0K

Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials

Ming Hao1, Richard Wang1, Wen Wang1

  • 1Cellular Biomedicine Group, 333 Guiping Road, Shanghai 200233, China; Cellular Biomedicine Group, 19925 Stevens Creek Blvd, Suite 100, Cupertino, CA 95014, USA.

Analytical Cellular Pathology (Amsterdam)
|February 15, 2017
PubMed

Insights

Stem cell therapy offers a promising approach for heart repair after myocardial infarction. This review examines stem-like cell treatments in preclinical and clinical studies for ischemic cardiomyopathy.

Area of Science:

  • Regenerative Medicine
  • Cardiology
  • Stem Cell Biology

Background:

  • The human heart has limited regenerative capacity, leading to heart failure after cardiomyocyte loss from injury or disease.
  • Stem cell therapy is a potential strategy to treat damaged myocardium and improve cardiac function.

Purpose of the Study:

  • To provide a comprehensive overview of stem-like cell treatments for ischemic cardiomyopathy.
  • To assess the feasibility and efficacy of stem cell therapy in preclinical and clinical studies.

Main Methods:

  • Review of preclinical and clinical studies on stem-like cell therapy for cardiac repair.
  • Evaluation of stem cell characteristics, including proliferation, differentiation, and immune compatibility.

Main Results:

  • Stem cell therapy shows promise for functional benefits in patients with heart conditions.
  • Ideal donor cells possess robust proliferation, low tumorigenicity, and immunocompatibility, differentiating into functional cardiomyocytes.

Conclusions:

  • Stem cell therapy is a feasible and potentially effective strategy for regenerating viable myocardium after myocardial infarction.
  • Further research and clinical studies are crucial to optimize stem cell treatments for ischemic cardiomyopathy and prevent heart failure.

More Related Videos

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.5K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
564
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
689
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
593
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
722